Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
05/2008
05/29/2008WO2008062476A2 Pharmaceutical composition comprising rosuvastatin or pharmaceutically accepatble salts thereof
05/29/2008WO2008062475A2 Pharmaceutical compositions of ursodiol
05/29/2008WO2008062470A2 Stabilized controlled release dosage form of gliclazide
05/29/2008WO2008062463A2 Improved process for the preparation of (r)-(+)-4-(ethyiamino)-3,4-dihydro-2-(3- methoxypropyl)-2h-thieno[3,2-e]-l,2-thiazine-6-sulfonamide-l,l-dioxide
05/29/2008WO2008062449A2 A novel pharmaceutical soft gel composition containing dexibuprofen and paracetamol
05/29/2008WO2008062437A2 Process for the preparation of sevelamer hydrochloride and formulation thereof
05/29/2008WO2008062436A2 Antimicrobial derivatives of anacardic acid and process for preparing the same
05/29/2008WO2008062435A2 Stabilised dosage forms of amlodipine besylate
05/29/2008WO2008062424A2 Substituted 4,5-dihydro-1h-pyrazole derivatives as cannabinoid modulators
05/29/2008WO2008062310A2 Elimination of the bacteria that cause pierce's disease
05/29/2008WO2008062274A2 Pharmaceutical formulations of nsaids for parentral use
05/29/2008WO2008062273A2 Solid oral dosage form having antidiabetic drug combination
05/29/2008WO2008062253A2 Stable pharmaceutical compositions of desloratadine and processes for preparation of polymorphic forms of desloratadine
05/29/2008WO2008062252A1 N-oxides of cytotoxic anthraquinones as hypoxia-targeting prodrugs in cancer treatment
05/29/2008WO2008062235A1 Therapeutic g-quadruplex ligands
05/29/2008WO2008062209A2 Dissolution and processing of cellulose
05/29/2008WO2008062206A2 Nucleoside aryl phosphoramidates and their use as anti-viral agents for the treatment of hepatitis c virus
05/29/2008WO2008062182A1 2- [ (2-substituted) -ind0lizin-3-yl] -2-oxo-acetamide derivatives as antifungal agents
05/29/2008WO2008062167A2 Melatonin derivatives and their use as antioxidants
05/29/2008WO2008062135A1 Use of adapalene for modulating the expression of il-1ra
05/29/2008WO2008062132A1 Use of adapalene for modulating the expression of cd1d or il-10
05/29/2008WO2008062066A1 Methods for improving bioavailability of a renin inhibitor
05/29/2008WO2008062047A1 Process for preparing a crystalline form of candesartan cilexetil
05/29/2008WO2008062044A1 2-hydroxy-1,3-diaminopropane derivatives
05/29/2008WO2008062040A1 Anticonvulsive pharmaceutical compositions
05/29/2008WO2008062026A1 5-sulfanylmethyl-pyrazolo [1,5-a] pyrimidin-7-ol derivatives as cxcr2 antagonists
05/29/2008WO2008062021A1 Vaginal delivery system for mirtazapine
05/29/2008WO2008062009A1 Delivery system for risperidone
05/29/2008WO2008062005A1 The use of aminoacetonitril compounds in the control of endoparasites in warm- blood animals.
05/29/2008WO2008061968A1 Benzimidazolone derivates in the treatment of pulmonary arterial hypertension
05/29/2008WO2008061966A2 New use of flibanserin
05/29/2008WO2008061955A1 Benzoisoindole derivatives and their use as ep4 receptor agonists
05/29/2008WO2008061938A2 Method for the dehydrogenation of hydrocarbons, entailing dehydrogenation and oxidation steps
05/29/2008WO2008061873A2 Stable powder formulation containing a novel anticholinergic agent
05/29/2008WO2008061805A1 Pharmaceutical compositions for the treatment of capillary arteriopathy
05/29/2008WO2008061795A2 N- (methyl) -1h- pyrazol- 3 -amine, n- (methyl) -pyridin-2-amine and n- (methyl) -thiaz0l-2-amine derivatives for the treatment of diseases associated with amyloid or amyloid-like proteins, like e.g. alzheimer's
05/29/2008WO2008061792A2 Tricarbonyl complexes with tridentate chelators for myocardium imaging
05/29/2008WO2008061781A1 Thiadiazole derivatives for the treatment of neuro-degenerative diseases
05/29/2008WO2008061754A1 Dietary or pharmaceutical compositions containing tricyclic diterpenes and derivatives thereof for the treatment of depression
05/29/2008WO2008061741A1 5-sulfanylmethyl-[1,2,4] triazol[1, 5-a] pyrimidin-7-ol derivatives as cxcr2 antagonists
05/29/2008WO2008061740A1 Pyrimidines and their use as cxcr2 receptor antagonists
05/29/2008WO2008061688A1 2 -alkyl- indazole compounds for the treatment of certain cns-related disorders
05/29/2008WO2008061671A2 Use of an indazolemethoxyalkanoic acid for reducing triglyceride, cholesterol and glucose levels
05/29/2008WO2008061657A1 Novel aza-bicyclic compounds and their use as stimulators of soluble guanylate cyclase
05/29/2008WO2008061647A1 Use of a compound as vegf inhibitor
05/29/2008WO2008061625A2 Transdermal therapeutic system for administering the active substance buprenorphine
05/29/2008WO2008061622A1 Crystalline forms of aliskiren hemifumarate
05/29/2008WO2008061612A1 Use of arginase inhibitors in the treatment of asthma and allergic rhinitis
05/29/2008WO2008061537A2 Oligonucleotides for modulating target rna activity
05/29/2008WO2008061536A1 Compositions and methods of using same for treatment of a disease or disorder of the eye and/or the adnexa of the eye
05/29/2008WO2008061535A1 Compositions comprising strontium and uses thereof in the treatment or prevention of gingivitis, periodontitis, periodontitis as a manifestation of systemic diseases, and necrotizing periodontal diseases.
05/29/2008WO2008061480A1 Novel mangiferin calcium salts, the method for its preparation and its use
05/29/2008WO2008061466A1 Synthetic methods of aclatonium napadisilate and analogs thereof
05/29/2008WO2008061456A1 The folacin-metformin compound and its manufacture
05/29/2008WO2008061447A1 A medicine for treating eczema and process of ointment thereof
05/29/2008WO2008061429A1 Use of triacontanol in preparation of medicaments for treatment of cancers
05/29/2008WO2008061428A1 The pharmaceutical formulations, use and preparation of triacontanol
05/29/2008WO2008061400A1 Fatty acid synthase inhibitors and medical uses thereof
05/29/2008WO2008061399A1 Fatty acid synthase inhibitor and its use
05/29/2008WO2008061375A1 Antiseptic
05/29/2008WO2008061373A1 Combination treatments for alzheimer's disease and similar diseases
05/29/2008WO2008061370A1 Diagnostic method to detect endometriosis
05/29/2008WO2008061308A1 Protein tyrosine phosphatase modulators
05/29/2008WO2008061306A1 Metal delivery agents and therapeutic uses of the same
05/29/2008WO2008061299A1 Method of treating diabetes
05/29/2008WO2008046109A3 Conjugates of artemisinin-related endoperoxides and hydrazone derivatives for the treatment of cancer
05/29/2008WO2008045673A3 Quinolone carboxylic acids, derivatives thereof, processes for its preparation and its use as antibacterial agents
05/29/2008WO2008045564A3 Carboxamide compounds and their use as antagonists of the chemokine ccr2 receptor
05/29/2008WO2008045507A3 Substituted tetracycline compounds for treatment of bacillus anthracis infections
05/29/2008WO2008045268A3 Pyrazolopyrimidines as cyclin dependent kinase inhibitors
05/29/2008WO2008045266A3 Pyrazolopyrimidiwes as cyclin dependent kinase inhibitor
05/29/2008WO2008043846A3 New isocarbostyril alkaloid derivatives having anti-proliferative and anti-migratory activities
05/29/2008WO2008042928A3 Oxadiazole and thiadiazole derivatives as mitotic kinesin inhibitors and methods of use thereof
05/29/2008WO2008041246A3 Injectable depot composition and its' process of preparation
05/29/2008WO2008041131A3 Anticoagulant compounds
05/29/2008WO2008041003A3 Hydroxycholesterols and its prodrugs for the treatment of insulin resistance and disorers asociated therewith
05/29/2008WO2008040649A3 Pyrazine-2-carboxamide derivatives as cb2 receptor modulators
05/29/2008WO2008040360A3 Use of hypothermia inducing drugs to treat ischemia
05/29/2008WO2008039218A3 Inhibitors of bruton's tyrosine kinase
05/29/2008WO2008038302A3 Therapeutic formulation comprising a sulfonylurea, metformin and a nitric oxide scavenger.
05/29/2008WO2008037935A3 Use of 6'-ethyl-lepimectine, 6'-methyl-lepimectine or derivatives thereof for the treatment of dermatological disorders in human beings
05/29/2008WO2008036540A3 Rho kinase inhibitors
05/29/2008WO2008034011A3 Methods of modulating cell proliferation and cyst formation in polycystic kidney and liver diseases
05/29/2008WO2008030830A3 Sustained-release composition and method of use thereof
05/29/2008WO2008027988A3 Methods of treating estrogen-responsive conditions by orphan nuclear receptor activation
05/29/2008WO2008025111A8 Biodegradable device for intraocular drug delivery
05/29/2008WO2008024846A3 Brimonidine and timolol compositions
05/29/2008WO2008024026A3 Use of 9-oxoacridine-10-acetic acid, its salts and esters for the treatment, prophylaxis or relapse prevention of prostate cancer
05/29/2008WO2008022807A3 Lipoxin a4 analogs for the treatment and prevention of intestinal fibrosis
05/29/2008WO2008021927A3 Hepatitis c virus inhibitors
05/29/2008WO2008021532A3 Treatment of inflammatory diseases
05/29/2008WO2008021369A3 Tricyclic compounds and its use as tyrosine kinase modulators
05/29/2008WO2008020820A3 Pharmaceutical compositions comprising aripiprazole
05/29/2008WO2008016678A3 Pharmaceutical dosage forms for (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid
05/29/2008WO2008016123A1 GSK-3β INHIBITOR
05/29/2008WO2008012440A3 Pyridazine and pyrrole compounds, processes for obtaining them and uses
05/29/2008WO2008012367A3 Compositions containing quaternary ammonium compounds
05/29/2008WO2008011562A3 Composition having effect of treating, preventing, or improving diabetes or diabetic complication and drink comprising the same
05/29/2008WO2008009802A3 Drugs comprising an inhibitor of class 1 alpha mannosidase for the treatment of sarcoglycanopathies
05/29/2008WO2008009655A3 Medical use of n-phenylpropenoyl-amino acid derivatives and related compounds
1 ... 3242 3243 3244 3245 3246 3247 3248 3249 3250 3251 3252 3253 3254 3255 3256 3257 3258 3259 3260 3261 3262 ... 7860